Evidence map›Paper›PMID 34040951›Full record

SynthesisGlobal heart2021

Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal.

Abhishek Sharma, Warren A Kaplan, Gautam Satheesh, Indra Prasad Poudyal, Pawan Gyawali, Dinesh Neupane, Parash Mani Bhandari, Milan Malla, Surendra Sapkota, Shiva Raj Mishra

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Global heart, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 6 countries.

Abhishek SharmaDepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts, US.
Warren A KaplanDepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts, US.
Gautam SatheeshThe George Institute for Global Health, Hyderabad, IN.
Indra Prasad PoudyalTribhuvan University, Institute of Medicine, Kathmandu, NP.
Pawan GyawaliTribhuvan University, Institute of Medicine, Kathmandu, NP.
Dinesh NeupaneNepal Development Society, Bharatpur, Chitwan, NP.
Parash Mani BhandariTribhuvan University, Institute of Medicine, Kathmandu, NP.
Milan MallaPatan Academy of Health Sciences, Lalitpur, NP.
Surendra SapkotaTribhuvan University, Institute of Medicine, Kathmandu, NP.
Shiva Raj MishraWorld Heart Federation, Salim Yusuf Emerging Leaders Progamme, Geneva, CH.
Tribhuvan University · NPBoston University · USGeorge Institute for Global Health · INJohns Hopkins University · USMinistry of Health and Population · NPPrecision Research (United States) · USUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Universal access to essential medicines and routine diagnostics is required to combat the growing burden of cardiovascular disease (CVD) and diabetes. Evaluating health systems and various access dimensions availability, affordability, accessibility, acceptability, and quality is crucial yet rarely performed, especially in low- and middle-income countries. Objective: To evaluate health system capacity and barriers in accessing diagnostics and essential medicines for CVD and diabetes in Nepal. Methods: We conducted a WHO/HAI nationally-representative survey in 45 health-facilities (public-sector: 11; private-sector: 34) in Nepal to collect availability and price data for 21 essential medicines for treating CVD and diabetes, during MayJuly 2017. Data for 13 routine diagnostics was obtained in 12 health facilities. Medicines were considered unaffordable if the lowest paid worker spends >1 days wage to purchase a monthly supply. To evaluate accessibility, we conducted facility exit interviews among 636 CVD patients. Accessibility (e.g., private-public health facility mix, travel to hospital/pharmacy) and acceptability (i.e. Nepals adoption of WHO Essential Medicine List, and patient medication adherence) were summarized using descriptive statistics, and we conducted a systematic review of relevant literature. We did not evaluate medicine quality. Results: We found that mean availability of generic medicines is low (<50%) in both public and private sectors, and less than one-third medicines met WHOs availability target (80%). Mean (SD) availability of diagnostics was 73.1% (26.8%). Essential medicines appear locally unaffordable. On average, the lowest-paid worker would spend 1.03 (public-sector) and 1.26 (private-sector) days wages to purchase a monthly supply. For a person undergoing CVD secondary preventive-interventions in the private sector, the associated expenditure would be 7.511.2% of monthly household income. Exit-interviews suggest that a long/expensive commute to health-facilities and poor medicine affordability constrain access. Conclusions: This study highlights critical gaps in Nepals health system capacity to offer basic health services to CVD and diabetes patients, owing to low availability, poor affordability and accessibility of essential medicines and diagnostics. Research and policy initiatives are needed to ensure uninterrupted supply of affordable essential medicines and diagnostics.

Indexed as

Cardiovascular DiseasesDiabetes MellitusDrugs, EssentialHealth Services AccessibilityHumansNepalDrugs, Essentialcardiovascular diseasediagnosticsessential medicineshealthcare deliveryNepalSustainable Development Goals

Identifiers

PMID34040951
PMCPMC8139299
OpenAlexW3160997078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.